JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Kodu・Aktsiate loetelu・Champions Oncology Inc

C
Champions Oncology Inc

Suletud

SektorTervishoid

5.73 -1.04

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.7

Max

5.75

Põhinäitajad
By Trading Economics
Sissetulek	-514K -278K
Müük	1.5M 17M
P/E Sektori keskmine	35.118 60.328
Aktsiakasum	-0.02
Kasumimarginaal	-1.679
Töötajad	213
EBITDA	-458K 154K

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	22. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	1.5M 84M
Eelmine avamishind	6.77
Eelmine sulgemishind	5.73

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

5.77 / 7.61 Toetus ja vastupanu

Champions Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Intertek Group Rejects EQT's Revised Offer

24. apr 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Scoring the Cook Era -- Barrons.com

24. apr 2026, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:09 UTC

Tulu

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. apr 2026, 19:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. apr 2026, 19:22 UTC

Tulu

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. apr 2026, 19:06 UTC

Tulu

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. apr 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. apr 2026, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. apr 2026, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Intertek Rejects Revised EQT Offer

24. apr 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. apr 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. apr 2026, 17:42 UTC

Tulu

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. apr 2026, 17:28 UTC

Tulu

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24. apr 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24. apr 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24. apr 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24. apr 2026, 17:09 UTC

Market Talk

Tulu

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24. apr 2026, 17:09 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 17:06 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24. apr 2026, 16:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24. apr 2026, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

24. apr 2026, 16:20 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 16:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

24. apr 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Champions Oncology Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Champions Oncology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.77 / 7.61Toetus ja vastupanu

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.